Literature DB >> 1370963

Problems of comorbidity in mortality after prostatectomy.

J Concato1, R I Horwitz, A R Feinstein, J G Elmore, S F Schiff.   

Abstract

OBJECTIVE: In recent studies of patients with benign prostatic hyperplasia (BPH), men undergoing transurethral resection of the prostate (TURP) had higher long-term mortality than men undergoing open prostatectomy. We tested the hypothesis that the higher mortality for patients undergoing TURP could have occurred if these patients were older and sicker at the time of surgery than patients undergoing open prostatectomy. DESIGN AND
SETTING: Retrospective cohort study at Yale-New Haven (Conn) Hospital. PATIENTS: Two hundred fifty-two men who underwent TURP or open prostatectomy from 1979 through 1981 for the treatment of BPH. MAIN OUTCOME MEASURES: Five-year mortality adjusted for age and severity of comorbid illness at the time of surgery.
RESULTS: The crude 5-year mortality rates were 17.5% (22 of 126 patients) for the TURP group and 13.5% (17 of 126 patients) for the open group. At the time of surgery, however, patients in the TURP group were sicker and older than patients in the open group. As the detail and quality of the assessment of comorbidity increased, the adjusted risk of TURP decreased. Improved classifications of comorbidity in three different forms of statistical analysis did not show an effect of type of prostatectomy on long-term mortality (Mantel-Haenszel relative risk, 1.03; 95% confidence interval, 0.57 to 1.87).
CONCLUSIONS: These results suggest that TURP does not increase long-term mortality after surgery for the treatment of BPH. Inadequate accounting for severity of illness may also affect other statistical "adjustments" used in research concerned with patient outcomes.

Entities:  

Mesh:

Year:  1992        PMID: 1370963

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  17 in total

1.  Outcomes and the management of health care. Health Services Research Group.

Authors: 
Journal:  CMAJ       Date:  1992-12-15       Impact factor: 8.262

Review 2.  Benign prostatic hyperplasia.

Authors:  A Melville; J Donovon; T Sheldon; T Peters
Journal:  Qual Health Care       Date:  1996-06

Review 3.  Comparative hospital databases: value for management and quality.

Authors:  R Cleary; R Beard; J Coles; B Devlin; A Hopkins; D Schumacher; I Wickings
Journal:  Qual Health Care       Date:  1994-03

4.  Comparing comorbid-illness indices assessing outcome variation: the case of prostatectomy.

Authors:  M A Krousel-Wood; A Abdoh; R Re
Journal:  J Gen Intern Med       Date:  1996-01       Impact factor: 5.128

5.  Improving the Safety of TURP.

Authors:  C G Roehrborn
Journal:  Rev Urol       Date:  2000

6.  Pharmacologic management of benign prostatic hyperplasia--changing times.

Authors:  A Y Smith
Journal:  West J Med       Date:  1994-11

Review 7.  Benign prostatic hyperplasia. Practical treatment guidelines.

Authors:  T Tammela
Journal:  Drugs Aging       Date:  1997-05       Impact factor: 3.923

8.  The Cochrane Lecture. The best and the enemy of the good: randomised controlled trials, uncertainty, and assessing the role of patient choice in medical decision making.

Authors:  K McPherson
Journal:  J Epidemiol Community Health       Date:  1994-02       Impact factor: 3.710

9.  Comparing healthcare outcomes.

Authors:  C Orchard
Journal:  BMJ       Date:  1994-06-04

10.  Racial differences in the impact of comorbidities on survival among elderly men with prostate cancer.

Authors:  Mary Putt; Judith A Long; Chantal Montagnet; Jeffrey H Silber; Virginia W Chang; J Sanford Schwartz; Craig Evan Pollack; Yu-Ning Wong; Katrina Armstrong
Journal:  Med Care Res Rev       Date:  2009-04-08       Impact factor: 3.929

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.